China Medical System Holdings Ltd. (HK:0867)
:0867
0867 Stock Chart & Stats
HK$14.20
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$14.20
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$6.84 - HK$15.63
Previous CloseN/A
Volume2.83M
Average Volume (3M)6.44M
Market Cap
HK$34.96B
Enterprise ValueHK$28.70B
Total Cash (Recent Filing)HK$5.97B
Total Debt (Recent Filing)HK$747.60M
Price to Earnings (P/E)13.0
Beta0.86
Next Earnings
Aug 13, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend Yield2.26%
Share Statistics
EPS (TTM)0.26
Shares Outstanding2,439,528,600
10 Day Avg. Volume4,711,227
30 Day Avg. Volume6,437,247
Financial Highlights & Ratios
PEG Ratio-1.85
Price to Book (P/B)1.61
Price to Sales (P/S)3.50
P/FCF Ratio114.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.48Price Target Upside30.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.84
Revenue Forecast (FY)HK$9.92B
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and rising equity give China Medical System durable financial flexibility to fund in-licensing, lifecycle investments, or targeted M&A without stressing liquidity. A conservative balance sheet reduces refinancing risk and supports multi-month capital allocation and strategic options.
High Product-level MarginsSustained high gross margins indicate structural pricing power and an advantaged product mix across hospital and retail channels. Healthy net margins provide internal funding for R&D and commercialization and act as a buffer against cyclical pressures over the medium term.
Pipeline Progress (ruxolitinib)NDA acceptance and priority review for a pediatric-capable topical ruxolitinib is a structural product-development milestone. If approved, it diversifies the portfolio into dermatology/pediatrics, shortens time-to-revenue, and strengthens medium-term commercial growth prospects in China.
Bears Say
Falling Returns On EquityThe marked drop in ROE signals weaker profitability and lower capital efficiency versus prior years. Persistently lower returns can limit the company's ability to fund growth internally and reduce long-term shareholder value unless operational performance is restored.
Weakened Cash GenerationMaterial decline in operating and free cash flow reduces internal funding for commercialization, trials, and acquisitions. Lower cash conversion increases reliance on external financing for strategic initiatives and weakens resilience to shocks over a multi-month horizon.
Revenue And Margin VolatilitySignificant swings in revenue and compressed operating margins reduce predictability of earnings and complicate long-term planning. Volatility undermines steady reinvestment in sales channels and lifecycle activities, making sustained growth harder to achieve without greater consistency.
China Medical System Holdings News
0867 FAQ
What was China Medical System Holdings Ltd.’s price range in the past 12 months?
China Medical System Holdings Ltd. lowest stock price was HK$6.84 and its highest was HK$15.63 in the past 12 months.
What is China Medical System Holdings Ltd.’s market cap?
China Medical System Holdings Ltd.’s market cap is HK$34.96B.
When is China Medical System Holdings Ltd.’s upcoming earnings report date?
China Medical System Holdings Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 128 days.
How were China Medical System Holdings Ltd.’s earnings last quarter?
China Medical System Holdings Ltd. released its earnings results on Mar 16, 2026. The company reported HK$0.262 earnings per share for the quarter, missing the consensus estimate of HK$0.33 by -HK$0.068.
Is China Medical System Holdings Ltd. overvalued?
According to Wall Street analysts China Medical System Holdings Ltd.’s price is currently Undervalued.
Does China Medical System Holdings Ltd. pay dividends?
China Medical System Holdings Ltd. pays a Semiannually dividend of HK$0.171 which represents an annual dividend yield of 2.26%. See more information on China Medical System Holdings Ltd. dividends here
What is China Medical System Holdings Ltd.’s EPS estimate?
China Medical System Holdings Ltd.’s EPS estimate is 0.46.
How many shares outstanding does China Medical System Holdings Ltd. have?
China Medical System Holdings Ltd. has 2,439,528,600 shares outstanding.
What happened to China Medical System Holdings Ltd.’s price movement after its last earnings report?
China Medical System Holdings Ltd. reported an EPS of HK$0.262 in its last earnings report, missing expectations of HK$0.33. Following the earnings report the stock price went up 2.439%.
Which hedge fund is a major shareholder of China Medical System Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:0867
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Medical System Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$18.48 (30.12% Upside)
HK$18.48 (30.12% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.75%
12-Months-Change
Fundamentals
Return on Equity
8.60%
Trailing 12-Months
Asset Growth
11.11%
Trailing 12-Months
Company Description
China Medical System Holdings Ltd.
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
0867 Stock 12 Month Forecast
Average Price Target
HK$18.48
▲(30.12% Upside)
Technical Analysis
The United Laboratories International Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Sihuan Pharmaceutical Holdings Group
―
China Resources Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---